Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside
Where Today's News Shapes Tomorrow
